Company profile for Minerva Neurosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with w...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe are innovative mechanisms of action. Our executive management team includes globally recognized specialists in central nervous system diseases addressing significant unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1601 Trapelo Road, Suite 286 Waltham, MA 02451
Telephone
Telephone
617-600-7373
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/19/3190924/32445/en/Minerva-Neurosciences-Appoints-Dr-Inderjit-Kaul-to-the-Company-s-Board-of-Directors.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181351/32445/en/Minerva-Neurosciences-Reports-Third-Quarter-2025-Financial-Results-and-Business-Updates.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/21/3170126/32445/en/Minerva-Neurosciences-Announces-Financing-of-up-to-200-Million-to-Advance-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia-Through-a-Phase-3-Confi.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/08/14/3133933/32445/en/Minerva-Neurosciences-Provides-Business-Updates-and-Second-Quarter-Financial-Results.html

GLOBENEWSWIRE
14 Aug 2025

https://www.globenewswire.com/news-release/2025/05/13/3079994/32445/en/Minerva-Neurosciences-Reports-First-Quarter-2025-Financial-Results-and-Business-Updates.html

GLOBENEWSWIRE
13 May 2025

https://www.globenewswire.com/news-release/2025/02/25/3031847/32445/en/Minerva-Neurosciences-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Business-Updates.html

GLOBENEWSWIRE
25 Feb 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty